

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

The risk of pyogenic liver abscess and endoscopic sphincterotomy: A population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018818
Article Type:	Research
Date Submitted by the Author:	05-Aug-2017
Complete List of Authors:	Peng, Yen-Chun Lin, Cheng-Li Sung, Fong-Chang
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Epidemiology
Keywords:	pyogenic liver abscess, endoscopic sphincterotomy, population-based cohort study

SCHOLARONE™
Manuscripts

Peer Review Only

The risk of pyogenic liver abscess and endoscopic sphincterotomy: A population-based cohort study

Yen-Chun Peng^{1,2}, Cheng-Li Lin^{3,4}, Fung-Chang Sung,^{3,5}

¹ Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

² National Yang-Ming University, Taipei, Taiwan

³ Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

⁴ College of Medicine, China Medical University, Taichung, Taiwan

⁵ Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

Address correspondence and requests for reprints to: Fung-Chang Sung, PhD. Professor, Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, No. 2, Yuh-Der Road, Taichung 404, Taiwan. Tel.: +886 4 22052121; Fax: +886 4 22336174. E-mail:sungfc2016@gmail.com

[Insert Running Title of <72 characters]

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Abstract.

Objectives: To evaluate the risk pyogenic liver abscess (PLA) in patients receiving endoscopic sphincterotomy (ES).

Setting: A population-based cohort study using data from Taiwans' National Health Insurance Research Database was conducted. Patients aged 20 or older who had undergone an ES were considered as the ES cohort. The dates for the first hospitalization of the ES patients were defined as the index dates.

Participants: patients in the ES and non-ES cohorts were selected by 1:1 matching ratio based on a propensity score. A total of 8174 sex-, age-, and index year-matched (1:1) pairs of patients receiving ES and 8174 patients without ES served as controls. Cox proportional hazards regression was employed to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between PLA and ES.

Results: The overall incidence of PLA was significantly higher in the ES cohort than in the non-ES cohort (4.20 vs 0.94, respectively, per 1000 person-year) with the adjusted HR (aHR) = 4.50 (95% CI = 3.38-6.58) A stratified analysis during the follow-up years revealed that when the ES cohort was compared with the non-ES cohort, they displayed a higher risk of PLA during the first follow-up year (aHR = 4.35, 95% CI = 2.26-8.39) which continued significantly over the next 4–5 years of follow-up.

Conclusions: Patients receiving ES are associated with having a higher risk of PLA.

Article summary

➤ Endoscopic sphincterotomy is a procedure which eliminates the anatomic barrier of the biliary tract and intestine, and is considered to be a well-established, standard procedure for treating

[Insert Running Title of <72 characters]

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

- 1
2 1 choledocholithiasis. There is not study have direct link the risk of pyogenic liver abscess in
3
4 2 patients receiving an Endoscopic sphincterotomy.
5
6
7 3 ➤ Patients receiving endoscopic sphincterotomy are associated with having a higher risk of
8
9 4 pyogenic liver abscess. The availability of these two large cohorts and follow-up conducted in
10
11 5 pyogenic liver abscess risk after patients receiving endoscopic sphincterotomy.
12
13
14 6 ➤ We used the code for only endoscopic sphincterotomy, and the details of underlying diseases,
15
16 7 which included mostly biliary, and pancreatic diseases are not clearly defined in the database.
17
18
19 8
20
21 9
22
23
24 10
25
26

27 **Introduction**

28
29 12 Endoscopic sphincterotomy (ES) is the most commonly used therapy for treatment of common
30
31 13 bile duct stones, and is today considered to be a well-established standard of treatment for
32
33 14 pancreato-biliary diseases. (1-3) Standard ES involves the application of electrocautery to create an
34
35 15 incision through the musculature of the biliary portion of the sphincter of Oddi and its use is
36
37 16 considered as a safe, therapeutic procedure. (4, 5)
38
39
40

41 17 Depending on the time frame after an ES, the complications resulting from an ES are both
42
43 18 short-term and long term. The percentage of short term complications is estimated to be
44
45 19 approximately 10 percent, where procedural related bleeding, perforation, pancreatitis, and
46
47 20 cardiopulmonary distress are considered as the short-term complications.(5) Long-term
48
49 21 complications following an ES include stone recurrence, papillary stenosis, and cholangitis, any of
50
51 22 which may which occur in approximately 6 to 24 percent of patients. (6-10)
52
53
54
55
56
57
58

59 [Insert Running Title of <72 characters]

60 For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2 1 Pyogenic liver abscesses (PLA) are the most common type of human visceral abscess. The
3
4 2 mechanism may be due to either the leakage of bowel contents or microbes which subsequently
5
6 3 spread to the liver via the portal circulation, or in the setting of a biliary infection. Risk factors for PLA
7
8 4 include diabetes mellitus, underlying hepatobiliary or pancreatic disease, end-stage renal disease and
9
10 5 the possible need for a liver transplant. (11-13) Additionally, geographic and host associations
11
12 6 should also be considered, such as *Klebsiella pneumoniae* which has been experienced in East
13
14 7 Asia.(14)

15
16
17
18
19 8 Regarding the long-term follow-up after ES, most previous studies displayed recurrent biliary
20
21 9 stones, cholangitis, stenosis and malignancy. (7-10, 15-17)

22
23
24 10 ES creates a communication of bowel contents to both the biliary system, and liver. Thus, it is
25
26 11 reasonable to consider that PLA is associated with ES. Up until now, there has been a lack of data
27
28 12 associating the risk of PLA with ES.

29
30
31
32
33
34 14 To illuminate the risk of PLA and ES, we conducted a population-based, cohort study to analyze
35
36 15 the risk of PLA among patients receiving an ES.

37 38 39 40 41 17 **Materials and Methods**

42 43 44 18 **Data Source**

45
46 19 This was a longitudinal, cohort study using the National Health Institute Research Database (NHIRD)
47
48 20 of the National Health Insurance (NHI) program in Taiwan. The NHI program began in 1995, and 99%
49
50 21 of the 23.74 million Taiwan residents became covered (18). The details of the NHI program and the
51
52 22 NHIRD have been well documented in previous studies (16, 19). Diseases were coded in the NHIRD
53
54 23 according to the 2001 International Classification of Diseases, Ninth revision, Clinical Modification

55
56
57
58
59 [Insert Running Title of <72 characters]

1 (ICD-9-CM). This study was approved by the Institutional Review Board (IRB) of China Medical
2 University and Hospital in Taiwan (CMUH104-REC2-115).

3 **Sampled Participants**

4 Patients aged 20 or older years who had undergone an ES (ICD-9-OP 51.84) were considered as the
5 ES cohort. The dates for the first hospitalization of the ES patients were defined as the index dates.
6 We excluded patients younger than 20 years, along with those having a history of PLA (ICD-9-CM
7 code 572.0) before the index date, any PLA diagnosed within 1 year after the index date, a history of
8 amoebic liver abscess (ICD-9-CM code 006.3), and/or those lacking information on their age and sex.
9 The non-ES cohort was identified during the same period occurring from the years 2000-2010, with
10 exclusion criteria similar to the ES cohort. Patients in the ES and non-ES cohorts were selected by a
11 1:1 matching ratio based on a propensity score (20). The propensity score was calculated using a
12 logistic regression to estimate the probability of the disease assignment, based on the baseline
13 variables, including year of ES diagnosis, age, gender, and comorbidities of congestive heart failure
14 (ICD-9-CM code 428), biliary stone (ICD-9-CM code 574), cancer (ICD-9-CM codes 140-208),
15 hypertension (ICD-9-CM codes 401-405), chronic obstructive pulmonary disease (ICD-9-CM codes
16 491, 492, 496), hyperlipidemia (ICD-9-CM code 272), alcoholic liver damage (ICD-9-CM code 571.0,
17 571.1, and 571.3), cirrhosis (ICD-9-CM codes 571.2, 571.5, and 571.6), cholangitis (ICD-9-CM code
18 576.1), cholecystitis (ICD-9-CM code 575), pancreatic diseases (ICD-9-CM code 577), chronic kidney
19 disease (ICD-9-CM codes 580-589), appendicitis (ICD-9-CM codes 540-543), inflammatory bowel
20 disease (ICD-9-CM codes 555, 556), and diverticulosis (ICD-9-CM codes 562).

21 **Follow-up and Outcome**

22 All of the patients were monitored up until either a diagnosis of PLA was made, they were censored
23 for withdrawal from the NHI program, their death, or December 31, 2011, whichever occurred first.

58 [Insert Running Title of <72 characters]

1 **Statistical analysis**

2 Distributions in demographic variables, including age, gender, and comorbidities were compared
3 between the ES and non-ES cohorts. The baseline characteristics of the ES and non-ES cohorts were
4 compared using standardized mean differences (21). A value of standardized mean differences
5 equaled .1 or less, which indicates there was a negligible difference in means between ES and non-ES
6 cohorts. Incidence density rates of PLA by gender, age, and comorbidity were calculated in both
7 cohorts. We assessed the cumulative incidence of PLA by using the Kaplan-Meier method in both the
8 ES and non- ES cohorts, with significance based on the log-rank test. Univariable and multivariable
9 Cox proportional hazard regressions were performed to measure the overall, gender-, age-,
10 comorbidity-, follow-up years- risk of developing PLA. Hazard ratios (HRs) and 95% confidence
11 intervals (CIs) were also estimated in the Cox model. The multivariate models were simultaneously
12 adjusted for age, sex, and the comorbidities of congestive heart failure, biliary stone, cancer,
13 hypertension, chronic obstructive pulmonary disease, hyperlipidemia, alcoholic liver damage,
14 cirrhosis, cholangitis, cholecystitis, pancreatic diseases, chronic kidney disease, appendicitis,
15 inflammatory bowel disease, and diverticulosis. The entire matching procedure and all statistical
16 analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). A two-tailed $P < .05$ was
17 considered significant.

18 **Results**

19 **Characteristics of patients**

20 Our study cohort consisted of 8,174 patients with ES and 8,174 patients without ES. The mean age
21 (\pm SD) of the ES and non-ES cohorts was 66.9 ± 15.0 and 68.5 ± 14.6 years, respectively (Table 1). Most
22 patients were men (53.1%). The major comorbidities were biliary stone (65.1% vs. 69.7%), and
23 hypertension (39.0% vs. 43.5%) in these study cohorts, followed by pancreatic diseases (17.2% vs.

[Insert Running Title of <72 characters]

18.9%), cholangitis (15.5% vs. 9.70%) and hyperlipidemia (9.69% vs. 12.9%). The average follow-up duration was 4.33 ± 2.71 years for the ES cohort and 4.30 ± 2.60 years for the non-ES cohort, respectively. Figure 1 shows that the cumulative incidence of PLA was higher in the ES cohort than that in the non-ES cohort by 3.33% at the end of the follow-up period (log-rank test $P < 0.001$).

5 **Incidence and adjusted hazard ratio of PLA after ES**

6 The overall incidence of PLA was significantly higher in the ES cohort than in the non-ES cohort (4.20 vs 0.94, respectively, per 1000 person-year) with the adjusted HR (aHR) = 4.50 (95% CI = 3.38-6.58) (Table 2). The ES cohort to the non-ES cohort aHR of PLA was significant for each status (including gender, age group, and those with or without comorbidity).

10 **Trend of PLA risk by stratified follow-up years**

11 A stratified analysis of the follow-up years revealed that the ES cohort when compared with the non-ES cohort, had higher risk of PLA during the first follow-up year (aHR = 4.35, 95% CI = 2.26-8.39) and remained significantly so during 4–5 years of follow-up (aHR = 4.59, 95% CI = 1.72-12.2). The risk of PLA remained even beyond 5 years of follow-up (aHR = 12.1, 95% CI = 2.80-52.2) (Table 3).

15 **Risk of Pyogenic liver abscess by Endoscopic sphincterotomy and Cholangitis**

16 Table 4 outlines the interaction effects of ES and cholangitis towards the risk of PLA. Relative to the non-ES cohort without cholangitis, the ES patients with cholangitis were at a much higher risk of PLA (aHR=6.64, 95% CI=3.82-11.5), when compared to patients with only cholangitis (aHR=3.77, 95% CI=1.69-8.41) or with only ES (aHR=5.48, 95% CI=3.56-8.44) (Table 4, the P-value of interaction=0.03).

20 **Discussion**

21 The association between PLA and ES is demonstrated by our results, which show that patients receiving ES have higher incidence rates of PLA than those in the control group (4.02 vs. 0.94 cases per 1000 person-years, $p < 0.001$). The adjusted HR for PLA was found to be 4.50 (95% CI 3.08–6.58)

[Insert Running Title of <72 characters]

1 for patients receiving EST, after adjusting for age, sex, and any possible comorbidities. The risk
2 becomes even more significant when the follow-up years exceed 5 (adjusted HR 12.1, 95% CI 2.80- 52.2).
3 Thus, PLA would be considered as one of the events which is associated with EST during long-term
4 follow-up. ES experience is also considered to be one of the risks of PLA.

5 There is no clearly set time for the duration of follow-up when discussing the long-term
6 complications of ES. A hospital-based study regarding endoscopic retreatment for biliary stones after
7 ES is defined to be 5 years, and then a follow-up choledochal conditions due to increased risk of
8 complications is suggested. (22) According to our results, PLA risk was determined to occur within 1
9 year after ES, and could be found to be increasing even more than that during the 5 year span. Thus,
10 PLA risk would be need to be carefully monitored throughout follow-up. Risk of PLA was found to be
11 more significant in non-comorbidity and young aged patients. We could explain that elderly patients
12 and those experiencing co-morbidity carry a higher risk of PLA.

13 After decades of development, ES is still considered to be the requisite standard of care, and
14 therefore has become the most commonly used procedure for the endoscopic treatment of biliary
15 diseases, including choledocholithiasis. ES is applied to cut the biliary sphincter in order to eliminate
16 the principal anatomic barrier impeding stone passage, and facilitate biliary manipulation. Upon
17 reviewing available literature, long-term choledochal complications after ES include recurrent
18 cholangitis, choledocholithiasis, biliary stenosis and cholecystitis. (6-10, 17) After ES, the anatomic
19 barrier of the hepato-biliary system and intestine is removed, resulting in the communication causing
20 an ascending migration of the bowel contents. The ascending movement would not be limited to
21 strictly the biliary system only. Intrahepatic biliary system and even in hepatic canaliculi would be
22 involved. Patients experiencing ES would remain under the risk of PLA.

1
2 1 PLA has become a worldwide health problem that is not limited to only Taiwan. When focusing
3
4 2 on the risks of PLA, diabetes, end-stage renal disease, hepatobiliary diseases, pancreatic diseases,
5
6 3 and the need for a liver transplant are all considered risk factors. (11-13, 23-25) Biliary disease is also
7
8 4 considered as a risk of PLA, but there is lack of mention to ES. (26) Based on our results, patients
9
10 5 receiving ES would also be considered to be a risk of PLA.
11
12
13

14 6 In the study, we first defined the association between ES and PLA, and recognized ES as a
15
16 7 definite risk factor for PLA. There are however several limitations for the present study. First, we
17
18 8 used the code for only ES, and any underlying diseases, which included mostly biliary, and pancreatic
19
20 9 diseases. However, we did adjust both biliary and pancreatic disease, as shown in table 1. Second,
21
22 10 the follow-up duration is around 4.3 years, with the longest set at about 7 years, due to the
23
24 11 limitations of the database. We would expect to see a more significant PLA risk appearing under a
25
26 12 longer follow-up period.
27
28
29
30

31 13 Our results demonstrate a significant risk of PLA during follow-up periods for patients receiving ES.
32
33 14 Further investigations including bacterial culture, details of biliary systems and the analysis of clinical
34
35 15 data, would be valuable studies that could be performed under a hospital-based inquiry.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributor ship statement

Author contributions: Conception and design: Yen-Chun Peng, Cheng-Li Lin, Fung-Chang Sung; Administrative support: Yen-Chun Peng; Collection and assembly of data: Yen-Chun Peng, Cheng-Li Lin, Fung-Chang Sung; Data analysis and interpretation: Yen-Chun Peng, Cheng-Li Lin, Fung-Chang Sung; Manuscript writing and revision: All authors; Final approval of manuscript: All authors.

competing interests

The authors declare no competing interests

Funding

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10601010036), Taiwan Clinical Trial Consortium for Stroke(MOST 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.

Data sharing statement

The Ministry of Health and Welfare must approved our application to access this data.

Any researcher interested in accessing this dataset can submit an application form to [Insert Running Title of <72 characters]

1
2
3
4 the Ministry of Health and Welfare requesting access. Please contact the staff of
5
6 MOHW (Email: stcarolwu@mohw.gov.tw) for further assistance. Taiwan Ministry of
7
8 Health and Welfare Address: No.488, Sec. 6, Zhongxiao E. Rd., Nangang Dist.,
9
10 Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848. All relevant data are
11
12
13
14
15 within the paper.
16
17
18
19
20

21 **References**

- 22
23
24 1. Dumonceau JM, Delhay M, Tringali A, et al. Endoscopic treatment of chronic
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Clinical
Guideline. *Endoscopy* 2012;44:784-800.
2. Maple JT, Ben-Menachem T, Anderson MA, et al. The role of endoscopy in the
evaluation of suspected choledocholithiasis. *Gastrointest Endosc* 2010;71:1-9.
3. Williams EJ, Green J, Beckingham I, et al. Guidelines on the management of
common bile duct stones (CBDS). *Gut* 2008;57:1004-21.
4. Binmoeller KF, Schafer TW. Endoscopic management of bile duct stones. *J Clin
Gastroenterol* 2001;32:106-18.
5. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary
sphincterotomy. *N Engl J Med* 1996;335:909-18.

[Insert Running Title of <72 characters]

- 1
2
3
4 6. Hawes RH, Cotton PB, Vallon AG. Follow-up 6 to 11 years after duodenoscopic
5
6 sphincterotomy for stones in patients with prior cholecystectomy. *Gastroenterology*
7
8
9 1990;98:1008-12.
10
- 11
12 7. Wojtun S, Gil J, Gietka W, et al. Endoscopic sphincterotomy for
13
14 choledocholithiasis: a prospective single-center study on the short-term and long-term
15
16 treatment results in 483 patients. *Endoscopy* 1997;29:258-65.
17
18
- 19
20 8. Yasuda I, Fujita N, Maguchi H, et al. Long-term outcomes after endoscopic
21
22 sphincterotomy versus endoscopic papillary balloon dilation for bile duct stones.
23
24
25 *Gastrointest Endosc* 2010;72:1185-91.
26
27
- 28
29 9. Sugiyama M, Suzuki Y, Abe N, et al. Endoscopic retreatment of recurrent
30
31 choledocholithiasis after sphincterotomy. *Gut* 2004;53:1856-9.
32
33
- 34
35 10. Sugiyama M, Atomi Y. Follow-up of more than 10 years after endoscopic
36
37 sphincterotomy for choledocholithiasis in young patients. *Br J Surg* 1998;85:917-21.
38
39
- 40
41 11. Mohsen AH, Green ST, Read RC, et al. Liver abscess in adults: ten years
42
43 experience in a UK centre. *Qjm* 2002;95:797-802.
44
45
- 46
47 12. Thomsen RW, Jepsen P, Sorensen HT. Diabetes mellitus and pyogenic liver
48
49 abscess: risk and prognosis. *Clin Infect Dis* 2007;44:1194-201.
50
51

52
53
54
55 [Insert Running Title of <72 characters]
56
57
58

- 1
2
3
4 13. Tsai LW, Chao PW, Ou SM, et al. Pyogenic liver abscess in end-stage renal
5
6 disease patients: a nationwide longitudinal study. *Hemodial Int* 2015;19:72-9.
7
8
9 14. Tsai F-C, Huang Y-T, Chang L-Y, et al. Pyogenic Liver Abscess as Endemic
10
11 Disease, Taiwan. *Emerging Infectious Diseases* 2008;14:1592-1600.
12
13
14
15 15. Kalaitzis J, Vezakis A, Fragulidis G, et al. Effects of endoscopic sphincterotomy
16
17 on biliary epithelium: a case-control study. *World J Gastroenterol* 2012;18:794-9.
18
19
20 16. Peng YC, Lin CL, Hsu WY, et al. Association of Endoscopic Sphincterotomy or
21
22 Papillary Balloon Dilatation and Biliary Cancer: A Population-Based Cohort Study.
23
24 *Medicine (Baltimore)* 2015;94:e926.
25
26
27
28 17. Sugiyama M, Atomi Y. Risk factors predictive of late complications after
29
30 endoscopic sphincterotomy for bile duct stones: long-term (more than 10 years)
31
32 follow-up study. *Am J Gastroenterol* 2002;97:2763-2767.
33
34
35
36 18. Database NHIR. Taiwan, <http://nhird.nhri.org.tw/en/index.html>. 2015 [cited;
37
38 Available from:
39
40
41
42 19. Wang CC, Chang CT, Lin CL, et al. Spinal cord injury is associated with an
43
44 increased risk of atrial fibrillation: A population-based cohort study. *Heart Rhythm*
45
46 2016;13:416-23.
47
48
49
50
51
52
53
54

55 [Insert Running Title of <72 characters]
56
57
58
59
60

- 1
2
3
4 20. Parsons LS. Performing a 1:N Case-Control Match on Propensity Score. In:
5
6 SUGI 29 Proceedings. Duke Owen, Conference Chair; 2004.
7
8
9 21. Austin PC. Balance diagnostics for comparing the distribution of baseline
10
11 covariates between treatment groups in propensity-score matched samples. *Stat Med*
12
13 2009;28:3083-107.
14
15
16 22. Keizman D, Shalom MI, Konikoff FM. An angulated common bile duct
17
18 predisposes to recurrent symptomatic bile duct stones after endoscopic stone
19
20 extraction. *Surg Endosc* 2006;20:1594-9.
21
22
23 23. Chan KS, Chen CM, Cheng KC, et al. Pyogenic liver abscess: a retrospective
24
25 analysis of 107 patients during a 3-year period. *Jpn J Infect Dis* 2005;58:366-8.
26
27
28 24. Kang SC, Hwang SJ. Impact of advanced age on inpatients with pyogenic liver
29
30 abscess in Taiwan: a nationwide claim-based analysis. *J Chin Med Assoc*
31
32 2011;74:539-43.
33
34
35 25. Tian LT, Yao K, Zhang XY, et al. Liver abscesses in adult patients with and
36
37 without diabetes mellitus: an analysis of the clinical characteristics, features of the
38
39 causative pathogens, outcomes and predictors of fatality: a report based on a large
40
41 population, retrospective study in China. *Clin Microbiol Infect* 2012;18:E314-30.
42
43
44
45
46
47
48
49
50
51
52
53
54

55 [Insert Running Title of <72 characters]
56
57
58
59
60

1
2
3
4 26. Cheng HC, Chang WL, Chen WY, et al. Long-term outcome of pyogenic liver
5
6 abscess: factors related with abscess recurrence. J Clin Gastroenterol 2008;42:1110-5.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

22 **Figure Legends**

23
24 Figure 1. Kaplan-Meier method determined the cumulative incidence of pyogenic liver
25
26 abscess compared between endoscopic sphincterotomy cohorts and comparisons
27
28 without endoscopic sphincterotomy.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 [Insert Running Title of <72 characters]
55
56
57
58
59
60

Acknowledgements:

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10601010036), Taiwan Clinical Trial Consortium for Stroke(MOST 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.

[Insert Running Title of <72 characters]

Table 1. Comparisons in demographic characteristics and comorbidities between patients with and without endoscopic sphincterotomy

	Endoscopic sphincterotomy				Standard difference
	No		Yes		
	(n=8174)		(n=8174)		
	n	%	n	%	
Age, mean(SD)†	68.5	14.6	66.9	15.0	0.11
Gender					
Women	3734	45.7	38232	46.9	0.02
Men	4440	54.3	4342	53.1	0.02
Comorbidity					
Congestive heart failure	564	6.90	491	6.01	0.04
Biliary stone	5695	69.7	5319	65.1	0.10

[Insert Running Title of <72 characters]

Cancer	687	8.40	580	7.10	0.06
Hypertension	3556	43.5	3186	39.0	0.09
Chronic obstructive lung disease	855	10.5	714	8.74	0.06
Hyperlipidemia	1052	12.9	792	9.69	0.10
Alcoholic liver damage	296	3.62	191	2.34	0.08
Cirrhosis	561	6.86	455	5.57	0.05
Cholangitis	793	9.70	1264	15.5	0.18
Cholecystitis	663	8.11	602	7.36	0.03
Pancreatic diseases	1544	18.9	1407	17.2	0.04
Chronic kidney disease	795	9.73	657	8.04	0.06
Appendicitis	167	2.04	152	1.86	0.01
Inflammatory bowel disease	34	0.42	20	0.24	0.03
Diverticulosis	215	2.63	206	2.52	0.01

[Insert Running Title of <72 characters]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

[Insert Running Title of <72 characters]

1 Table 2. Incidence and adjusted hazard ratio of Pyogenic liver abscess stratified by sex, age and
 2 comorbidity compared patients with and without endoscopic sphincterotomy

Endoscopic sphincterotomy								
No			Yes			Crude HR [†] (95 % CI)	Adjusted HR ^{&} (95 % CI)	
Event	PY	Rate [#]	Event	PY	Rate [#]			
All	33	35113	0.94	149	35454	4.20	4.50(3.08, 6.56)***	4.50(3.08, 6.58)***
Gender								
Women	12	16394	0.73	67	16970	3.95	5.42(2.93, 10.0)***	5.41(2.92, 10.0)***
Men	21	18719	1.12	82	18483	4.44	3.97(2.46, 6.42)***	4.02(2.48, 6.53)***
Age								
≤49	4	4928	0.81	23	5558	4.14	5.16(1.79, 14.9)**	7.30(2.42, 22.0)***
50-64	10	7762	1.29	38	8620	4.41	3.47(1.73, 6.96)***	3.30(1.63, 6.69)***
65+	19	22423	0.85	88	21276	4.14	4.90(2.99, 8.05)***	4.80(2.91, 7.90)***
Comorbidity								
No	2	4721	0.42	14	1715	8.16	20.4(4.60, 90.2)***	19.9(4.46, 88.6)***
Yes	31	30392	1.02	135	33738	4.00	3.95(2.67, 5.83)***	3.90(2.64, 5.78)***

3 Rate[#], incidence rate, per 1000 person-years

4 Crude HR[†], relative hazard ratio

5 Adjusted HR[&], adjusted hazard ratio, adjusted for age, sex, and comorbidity of congestive heart
 6 failure, biliary stone, cancer, hypertension, chronic obstructive lung disease, hyperlipidemia,

[Insert Running title of <72 characters]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 alcoholic liver damage, cirrhosis, cholangitis, cholecystitis, pancreatic diseases, chronic kidney
2 disease, appendicitis, inflammatory bowel disease, and diverticulosis.

3 *p<0.05, **p<0.01,***p<0.001

For peer review only

[Insert Running title of <72 characters]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3 Trends of Pyogenic liver abscess risks by stratified follow-up years

Endoscopic sphincterotomy									
		No			Yes				
Follow-up time, years	Event	PY	Rate [#]	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	
	≤1	11	15458	0.71	52	15319	3.39	4.81(2.51, 9.23)***	4.35(2.26, 8.39)***
2-3	15	9931	1.51	52	9785	5.31	3.54(1.99, 6.28)***	3.64(2.04, 6.50)***	
4-5	5	5512	0.91	22	5692	3.87	4.27(1.62, 11.3)**	4.59(1.72, 12.2)**	
>5	2	4213	0.47	23	4658	4.94	10.4(2.45, 44.0)**	12.1(2.80, 52.2)***	

1 Rate[#], incidence rate, per 1000 person-years2 Crude HR[†], relative hazard ratio

3 Adjusted HR[‡], adjusted hazard ratio, adjusted for age, sex, and comorbidity of congestive heart
 4 failure, biliary stone, cancer, hypertension, chronic obstructive lung disease, hyperlipidemia,
 5 alcoholic liver damage, cirrhosis, cholangitis, cholecystitis, pancreatic diseases, chronic kidney
 6 disease, appendicitis, inflammatory bowel disease, and diverticulosis.

7 *p<0.05, **p<0.01,***p<0.001

8

9

10

11

12

13

14

[Insert Running title of <72 characters]

1 Table 4. Cox Proportional Hazard Regression Analysis for the risk of pyogenic liver abscess by
 2 endoscopic sphincterotomy and Cholangitis


Variables		Event	Rate [#]	Adjusted HR [†] (95% CI)	p-value [#]
Endoscopic sphincterotomy	Cholangitis				0.03
No	No	25	0.78	1(Reference)	
No	Yes	8	2.72	3.77(1.69, 8.41)**	
Yes	No	122	4.02	5.48(3.56, 8.44)***	
Yes	Yes	27	5.32	6.64(3.82, 11.5)***	

3 Rate[#], per 1,000 person-year;

4 † Model was adjusted for age, sex and other comorbidities. *p<0.05, **p<0.01, ***p<0.001

5 #p-value for interaction

[Insert Running title of <72 characters]



BMJ Open

The risk of pyogenic liver abscess and endoscopic sphincterotomy: A population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018818.R1
Article Type:	Research
Date Submitted by the Author:	17-Jan-2018
Complete List of Authors:	Peng, Yen-Chun ; Taichung Veterans General Hospital, Internal medicine; National Yang-Ming University, internal medicine Lin, Cheng-Li; China Medical University Hospital, Management Office for Health Data; China Medical University, College of Medicine Sung, Fung-Chang; China Medical University, School of Medicine; China Medical University, Institution of Clinical Medical Science
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Epidemiology
Keywords:	pyogenic liver abscess, endoscopic sphincterotomy, population based study

SCHOLARONE™
Manuscripts

The risk of pyogenic liver abscess and endoscopic sphincterotomy: A population-based cohort study

Yen-Chun Peng^{1,2}, Cheng-Li Lin^{3,4}, Fung-Chang Sung,^{3,5}

¹ Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

² National Yang-Ming University, Taipei, Taiwan

³ Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

⁴ College of Medicine, China Medical University, Taichung, Taiwan

⁵ Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

Address correspondence and requests for reprints to: Fung-Chang Sung, PhD.

Professor, Graduate Institute of Clinical Medical Science and School of Medicine,

College of Medicine, China Medical University, No. 2, Yuh-Der Road, Taichung 404,

Taiwan. Tel.: +886 4 22052121; Fax: +886 4 22336174. E-mail:sungfc2016@gmail.com

Abstract.

1 **Objectives:** To evaluate the risk pyogenic liver abscess (PLA) in patients receiving
2 endoscopic sphincterotomy (ES).
3

4 **Setting:** A population-based cohort study using data from Taiwans' National Health
5 Insurance Research Database was conducted. Patients aged 20 or older who had undergone
6 an ES were considered as the ES cohort. The dates for the first hospitalization of the ES
7 patients were defined as the index dates.
8

9 **Participants:** patients in the ES and non-ES cohorts were selected by 1:1 matching ratio
10 based on a propensity score. A total of 8174 sex-, age-, and index year-matched (1:1) pairs of
11 patients receiving ES and 8174 patients without ES served as controls. Cox proportional
12 hazards regression was employed to calculate the hazard ratios (HRs) and 95% confidence
13 intervals (CIs) for the association between PLA and ES.
14

15 **Results:** The overall incidence of PLA was significantly higher in the ES cohort than in the
16 non-ES cohort (4.20 vs 0.94, respectively, per 1000 person-year) with the adjusted HR (aHR)
17 = 4.50 (95% CI = 3.38-6.58) A stratified analysis during the follow-up years revealed that
18 when the ES cohort was compared with the non-ES cohort, they displayed a higher risk of
19 PLA during the first follow-up year (aHR = 4.35, 95% CI = 2.26-8.39) which continued
20 significantly over the next 4–5 years of follow-up.
21

22 **Conclusions:** Patients receiving ES are associated with having a higher risk of PLA.
23
24

25 **Article summary**

26 ➤ Endoscopic sphincterotomy is a procedure which eliminates the anatomic barrier of the
27 biliary tract and intestine, and is considered to be a well-established, standard procedure
28 for treating choledocholithiasis. There is no study have direct link the risk of pyogenic liver
29 abscess in patients receiving an Endoscopic sphincterotomy.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2 1 ➤ Patients receiving endoscopic sphincterotomy are associated with having a higher risk of
3
4 2 pyogenic liver abscess. The availability of these two large cohorts and follow-up
5
6 3 conducted in pyogenic liver abscess risk after patients receiving endoscopic
7
8 4 sphincterotomy.
9
10
11 5 ➤ We used the code for only endoscopic sphincterotomy, and the details of underlying
12
13 6 diseases, which included mostly biliary, and pancreatic diseases are not clearly defined
14
15 7 in the database.
16
17
18 8
19
20 9
21
22
23 10

24 25 **Introduction**

26
27 12 Endoscopic sphincterotomy (ES) is the most commonly used therapy for treatment of
28
29 13 common bile duct stones, and is today considered to be a well-established standard of
30
31 14 treatment for pancreato-biliary diseases. (1-3) Standard ES involves the application of
32
33 15 electrocautery to create an incision through the musculature of the biliary portion of the
34
35 16 sphincter of Oddi and its use is considered as a safe, therapeutic procedure. (4, 5)
36
37
38

39 17 Depending on the time frame after an ES, the complications resulting from an ES are
40
41 18 both short-term and long term. The percentage of short term complications is estimated to be
42
43 19 approximately 10 percent, where procedural related bleeding, perforation, pancreatitis, and
44
45 20 cardiopulmonary distress are considered as the short-term complications.(5) Long-term
46
47 21 complications following an ES include stone recurrence, papillary stenosis, and cholangitis,
48
49 22 any of which may which occur in approximately 6 to 24 percent of patients. (6-10)
50
51

52 23 Pyogenic liver abscesses (PLA) are the most common type of human visceral abscess.
53
54 24 The mechanism may be due to either the leakage of bowel contents or microbes which
55
56 25 subsequently spread to the liver via the portal circulation, or in the setting of a biliary infection.
57
58
59

1 Risk factors for PLA include diabetes mellitus, underlying hepatobiliary or pancreatic disease,
2 end-stage renal disease and the possible need for a liver transplant. (11-13) Additionally,
3 geographic and host associations should also be considered, such as Klebsiella
4 pneumoniae which has been experienced in East Asia.(14)

5 Regarding the long-term follow-up after ES, most previous studies displayed recurrent
6 biliary stones, cholangitis, stenosis and malignancy. (7-10, 15-17)

7 ES creates a communication of bowel contents to both the biliary system, and liver. Thus,
8 it is reasonable to consider that PLA is associated with ES. Up until now, there has been a
9 lack of data associating the risk of PLA with ES.

10
11 To illuminate the risk of PLA and ES, we conducted a population-based, cohort study to
12 analyze the risk of PLA among patients receiving an ES.

13 14 **Materials and Methods**

15 **Data Source**

16 This was a longitudinal, cohort study using the National Health Institute Research Database
17 (NHIRD) of the National Health Insurance (NHI) program in Taiwan. The NHI program began
18 in 1995, and 99% of the 23.74 million Taiwan residents became covered (18). The details of
19 the NHI program and the NHIRD have been well documented in previous studies (16, 19).
20 Diseases were coded in the NHIRD according to the 2001 International Classification of
21 Diseases, Ninth revision, Clinical Modification (ICD-9-CM). This study was approved by the
22 Institutional Review Board (IRB) of China Medical University and Hospital in Taiwan
23 (CMUH104-REC2-115).

24 **Sampled Participants**

1 Patients aged 20 or older years who had undergone an ES (ICD-9-OP 51.84) were
2 considered as the ES cohort. The dates for the first hospitalization of the ES patients were
3 defined as the index dates. We excluded patients younger than 20 years, along with those
4 having a history of PLA (ICD-9-CM code 572.0) before the index date, any PLA diagnosed
5 within 1 year after the index date, a history of amoebic liver abscess (ICD-9-CM code 006.3),
6 and/or those lacking information on their age and sex. The non-ES cohort was identified
7 during the same period occurring from the years 2000-2010, with exclusion criteria similar to
8 the ES cohort. Patients in the ES and non-ES cohorts were selected by a 1:1 matching ratio
9 based on a propensity score (20). The propensity score was calculated using a logistic
10 regression to estimate the probability of the disease assignment, based on the baseline
11 variables, including year of ES diagnosis, age, gender, and comorbidities of congestive heart
12 failure (ICD-9-CM code 428), biliary stone (ICD-9-CM code 574), cancer (ICD-9-CM codes
13 140-208), hypertension (ICD-9-CM codes 401-405), chronic obstructive pulmonary disease
14 (ICD-9-CM codes 491, 492, 496), hyperlipidemia (ICD-9-CM code 272), alcoholic liver
15 damage (ICD-9-CM code 571.0, 571.1, and 571.3), cirrhosis (ICD-9-CM codes 571.2, 571.5,
16 and 571.6), cholangitis (ICD-9-CM code 576.1), cholecystitis (ICD-9-CM code 575),
17 pancreatic diseases (ICD-9-CM code 577), chronic kidney disease (ICD-9-CM codes
18 580-589), appendicitis (ICD-9-CM codes 540-543), inflammatory bowel disease (ICD-9-CM
19 codes 555, 556), and diverticulosis (ICD-9-CM codes 562).

20 **Follow-up and Outcome**

21 All of the patients were monitored up until either a diagnosis of PLA was made, they were
22 censored for withdrawal from the NHI program, their death, or December 31, 2011, whichever
23 occurred first.

24 **Statistical analysis**

1 Distributions in demographic variables, including age, gender, and comorbidities were
2 compared between the ES and non-ES cohorts. The baseline characteristics of the ES and
3 non-ES cohorts were compared using standardized mean differences (21). A value of
4 standardized mean differences equaled .1 or less, which indicates there was a negligible
5 difference in means between ES and non-ES cohorts. Incidence density rates of PLA by
6 gender, age, and comorbidity were calculated in both cohorts. We assessed the cumulative
7 incidence of PLA by using the Kaplan-Meier method in both the ES and non- ES cohorts, with
8 significance based on the log-rank test. Univariable and multivariable Cox proportional hazard
9 regressions were performed to measure the overall, gender-, age-, comorbidity-, follow-up
10 years- risk of developing PLA. Hazard ratios (HRs) and 95% confidence intervals (CIs) were
11 also estimated in the Cox model. The multivariate models were simultaneously adjusted for
12 age, sex, and the comorbidities of congestive heart failure, biliary stone, cancer, hypertension,
13 chronic obstructive pulmonary disease, hyperlipidemia, alcoholic liver damage, cirrhosis,
14 cholangitis, cholecystitis, pancreatic diseases, chronic kidney disease, appendicitis,
15 inflammatory bowel disease, and diverticulosis. The entire matching procedure and all
16 statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). A
17 two-tailed $P < .05$ was considered significant.

18 **Results**

19 **Characteristics of patients**

20 Our study cohort consisted of 8,174 patients with ES and 8,174 patients without ES. The
21 mean age (\pm SD) of the ES and non-ES cohorts was 66.9 ± 15.0 and 68.5 ± 14.6 years,
22 respectively (Table 1). Most patients were men (53.1%). The major comorbidities were biliary
23 stone (65.1% vs. 69.7%), and hypertension (39.0% vs. 43.5%) in these study cohorts,
24 followed by pancreatic diseases (17.2% vs. 18.9%), cholangitis (15.5% vs. 9.70%) and
25 hyperlipidemia (9.69% vs. 12.9%). The average follow-up duration was 4.33 ± 2.71 years for

1 the ES cohort and 4.30 ± 2.60 years for the non-ES cohort, respectively. Figure 1 shows that
2 the cumulative incidence of PLA was higher in the ES cohort than that in the non-ES cohort by
3 3.33% at the end of the follow-up period (log-rank test $P < 0.001$).

4 **Incidence and adjusted hazard ratio of PLA after ES**

5 The overall incidence of PLA was significantly higher in the ES cohort than in the non-ES
6 cohort (4.20 vs 0.94, respectively, per 1000 person-year) with the adjusted HR (aHR) = 4.50
7 (95% CI = 3.38-6.58) (Table 2). The ES cohort to the non-ES cohort aHR of PLA was
8 significant for each status (including gender, age group, and those with or without
9 comorbidity).

10 **Trend of PLA risk by stratified follow-up years**

11 A stratified analysis of the follow-up years revealed that the ES cohort when compared with
12 the non-ES cohort, had higher risk of PLA during the first follow-up year (aHR = 4.35, 95% CI
13 = 2.26-8.39) and remained significantly so during 4–5 years of follow-up (aHR = 4.59, 95% CI
14 = 1.72-12.2). The risk of PLA remained even beyond 5 years of follow-up (aHR = 12.1, 95% CI
15 = 2.80-52.2) (Table 3).

16 **Risk of Pyogenic liver abscess by Endoscopic sphincterotomy and Cholangitis**

17 Table 4 outlines the interaction effects of ES and cholangitis towards the risk of PLA. Relative
18 to the non-ES cohort without cholangitis, the ES patients with cholangitis were at a much
19 higher risk of PLA (aHR=6.64, 95% CI=3.82-11.5), when compared to patients with only
20 cholangitis (aHR=3.77, 95% CI=1.69-8.41) or with only ES (aHR=5.48, 95% CI=3.56-8.44)
21 (Table 4, the P-value of interaction=0.03).

22 **Discussion**

23 The association between PLA and ES is demonstrated by our results, which show that
24 patients receiving ES have higher incidence rates of PLA than those in the control group (4.02
25 vs. 0.94 cases per 1000 person-years, $p < 0.001$). The adjusted HR for PLA was found to be

1
2 1 4.50 (95% CI 3.08–6.58) for patients receiving EST, after adjusting for age, sex, and any
3
4 2 possible comorbidities. The risk becomes even more significant when the follow-up years
5
6 3 exceed 5 (adjust HR12.1, 95% CI 2.80- 52.2). Thus, PLA would be considered as one of the
7
8 4 events which is associated with EST during long-term follow-up. ES experience is also
9
10 5 considered to be one of the risks of PLA.
11
12

13
14 6 There is no clearly set time for the duration of follow-up when discussing the long-term
15
16 7 complications of ES. A hospital-based study regarding endoscopic retreatment for biliary
17
18 8 stones after ES is defined to be 5 years, and then a follow-up choledochal conditions due to
19
20 9 increased risk of complications is suggested. (22) According to our results, PLA risk was
21
22 10 determined to occur within 1 year after ES, and could be found to be increasing even more
23
24 11 than that during the 5 year span. Thus, PLA risk would be need to be carefully monitored
25
26 12 throughout follow-up. Risk of PLA was found to be more significant in non-comorbridity and
27
28 13 young aged patients. We could explain that elderly patients and those experiencing
29
30 14 co-morbidity carry a higher risk of PLA.
31
32
33

34 15 After decades of development, ES is still considered to be the requisite standard of care,
35
36 16 and therefore has become the most commonly used procedure for the endoscopic treatment
37
38 17 of biliay diseases, including choledocholithiasis. ES is applied to cut the biliary sphincter in
39
40 18 order to eliminate the principal anatomic barrier impeding stone passage, and facilitate biliary
41
42 19 manipulation. Upon reviewing available literature, long-term choledochal complications after
43
44 20 ES include recurrent cholangitis, choledocholithiasis, biliary stenosis and cholecystitis. (6-10,
45
46 21 17) After ES, the anatomic barrier of the hepato-biliary system and intestine is removed,
47
48 22 resulting in the communication causing an ascending migration of the bowel contents. The
49
50 23 ascending movement would not be limited to strictly the biliary system only. Intrahepatic
51
52 24 biliary system and even in hepatic cananliculi would be involved. Patients experiencing ES
53
54 25 would remain under the risk of PLA.
55
56
57
58
59
60

1
2 1 There seemed to be no large survey for PLA after ES except for case reports.(23, 24)
3
4 2 Taneka et al report about 5 PLA in 419 ES patients in a long-term follow up for ES study. (25)
5
6 3 Interestingly, a smaller study about PLA demonstrated that patients with ES is good
7
8 prognostic factor associated resolution within 6 weeks.(26) Based on the communicating with
9
10 4 intestine, risk of PLA were also found in patients receiving pancreatitcoduodenostomy, and
11
12 5 hepatojejunostomy. (27, 28)
13
14 6

15
16 7 PLA has become a worldwide health problem that is not limited to only Taiwan. When
17
18 8 focusing on the risks of PLA, diabetes, end-stage renal disease, hepatobiliary diseases,
19
20 9 pancreatic diseases, and the need for a liver transplant are all considered risk factors. (11-13,
21
22 10 29-31) Biliary disease is also considered as a risk of PLA, but there is lack of mention to ES.
23
24 11 (32) Based on our results, patients receiving ES would also be considered to be a risk of PLA.
25
26

27 12 In the study, we first defined the association between ES and PLA, and recognized ES
28
29 13 as a definite risk factor for PLA. There are however several limitations for the present study.
30
31 14 First, we used the code for only ES, and any underlying diseases, which included mostly
32
33 15 biliary, and pancreatic diseases. However, we did adjust both biliary and pancreatic disease,
34
35 16 as shown in table 1. Second, the follow-up duration is around 4.3 years, with the longest set at
36
37 17 about 7 years, due to the limitations of the database. We would expect to see a more
38
39 18 significant PLA risk appearing under a longer follow-up period.
40
41

42
43 19 Our results demonstrate a significant risk of PLA during follow-up periods for patients
44
45 20 receiving ES. Further investigations including bacterial culture, details of biliary systems and
46
47 21 the analysis of clinical data, would be valuable studies that could be performed under a
48
49 22 hospital-based inquiry.
50
51
52
53
54
55
56
57
58
59
60

Contributor ship statement

Author contributions: Conception and design: Yen-Chun Peng, Cheng-Li Lin, Fung-Chang Sung; Administrative support: Yen-Chung Peng; Collection and assembly of data: Yen-Chun Peng, Cheng-Li Lin, Fung-Chang Sung; Data analysis and interpretation: Yen-Chung Peng, Cheng-Li Lin, Fung-Chang Sung; Manuscript writing and revision: all authors; Final approval of manuscript: all authors.

competing interests

The authors declare no competing interests

Funding

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10601010036), Taiwan Clinical Trial Consortium for Stroke(MOST 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.

Data sharing statement

The Ministry of Health and Welfare must approved our application to access this data.

Any researcher interested in accessing this dataset can submit an application form to the Ministry of Health and Welfare requesting access. Please contact the staff of

1
2
3
4 MOHW (Email: stcarolwu@mohw.gov.tw) for further assistance. Taiwan Ministry of
5
6 Health and Welfare Address: No.488, Sec. 6, Zhongxiao E. Rd., Nangang Dist.,
7
8
9 Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848. All relevant data are
10
11
12 within the paper.
13
14
15
16
17

18 **References**

- 20 1. Dumonceau JM, Delhaye M, Tringali A, et al. Endoscopic treatment of chronic
21 pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Clinical
22 Guideline. *Endoscopy* 2012;44:784-800.
- 23 2. Maple JT, Ben-Menachem T, Anderson MA, et al. The role of endoscopy in the
24 evaluation of suspected choledocholithiasis. *Gastrointest Endosc* 2010;71:1-9.
- 25 3. Williams EJ, Green J, Beckingham I, et al. Guidelines on the management of
26 common bile duct stones (CBDS). *Gut* 2008;57:1004-21.
- 27 4. Binmoeller KF, Schafer TW. Endoscopic management of bile duct stones. *J Clin*
28 *Gastroenterol* 2001;32:106-18.
- 29 5. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary
30 sphincterotomy. *N Engl J Med* 1996;335:909-18.
- 31 6. Hawes RH, Cotton PB, Vallon AG. Follow-up 6 to 11 years after duodenoscopic
32 sphincterotomy for stones in patients with prior cholecystectomy. *Gastroenterology*
33 1990;98:1008-12.
- 34 7. Wojtun S, Gil J, Gietka W, et al. Endoscopic sphincterotomy for
35 choledocholithiasis: a prospective single-center study on the short-term and long-term
36 treatment results in 483 patients. *Endoscopy* 1997;29:258-65.
- 37 8. Yasuda I, Fujita N, Maguchi H, et al. Long-term outcomes after endoscopic
38 sphincterotomy versus endoscopic papillary balloon dilation for bile duct stones.
39 *Gastrointest Endosc* 2010;72:1185-91.
- 40 9. Sugiyama M, Suzuki Y, Abe N, et al. Endoscopic retreatment of recurrent
41 choledocholithiasis after sphincterotomy. *Gut* 2004;53:1856-9.
- 42 10. Sugiyama M, Atomi Y. Follow-up of more than 10 years after endoscopic
43 sphincterotomy for choledocholithiasis in young patients. *Br J Surg* 1998;85:917-21.
- 44 11. Mohsen AH, Green ST, Read RC, et al. Liver abscess in adults: ten years
45 experience in a UK centre. *Qjm* 2002;95:797-802.

12. Thomsen RW, Jepsen P, Sorensen HT. Diabetes mellitus and pyogenic liver abscess: risk and prognosis. *Clin Infect Dis* 2007;44:1194-201.
13. Tsai LW, Chao PW, Ou SM, et al. Pyogenic liver abscess in end-stage renal disease patients: a nationwide longitudinal study. *Hemodial Int* 2015;19:72-9.
14. Tsai F-C, Huang Y-T, Chang L-Y, et al. Pyogenic Liver Abscess as Endemic Disease, Taiwan. *Emerging Infectious Diseases* 2008;14:1592-1600.
15. Kalaitzis J, Vezakis A, Fragulidis G, et al. Effects of endoscopic sphincterotomy on biliary epithelium: a case-control study. *World J Gastroenterol* 2012;18:794-9.
16. Peng YC, Lin CL, Hsu WY, et al. Association of Endoscopic Sphincterotomy or Papillary Balloon Dilatation and Biliary Cancer: A Population-Based Cohort Study. *Medicine (Baltimore)* 2015;94:e926.
17. Sugiyama M, Atomi Y. Risk factors predictive of late complications after endoscopic sphincterotomy for bile duct stones: long-term (more than 10 years) follow-up study. *Am J Gastroenterol* 2002;97:2763-2767.
18. Database NHIR. Taiwan, <http://nhird.nhri.org.tw/en/index.html>. 2015.
19. Wang CC, Chang CT, Lin CL, et al. Spinal cord injury is associated with an increased risk of atrial fibrillation: A population-based cohort study. *Heart Rhythm* 2016;13:416-23.
20. Parsons LS, Ovation Research Group. SUGI 29. Seattle, Washington; 2004. Performing a 1:N Case-Control Match on Propensity Score; pp. 165–29.
21. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009;28:3083-107.
22. Keizman D, Shalom MI, Konikoff FM. An angulated common bile duct predisposes to recurrent symptomatic bile duct stones after endoscopic stone extraction. *Surg Endosc* 2006;20:1594-9.
23. Correa Bonito A, Mora-Guzman I, Garcia-Sanz I, et al. Liver abscess after endoscopic retrograde cholangiopancreatography with presence of *Actinomyces naeslundii*. *Cir Esp* 2017;95:51-52.
24. Gavini S, Kadiyala S, Venkatarami Reddy V, et al. Large liver abscess after ERCP and laparoscopic cholecystectomy. *HPB*;18:e315-e316.
25. Tanaka M, Takahata S, Konomi H, et al. Long-term consequence of endoscopic sphincterotomy for bile duct stones. *Gastrointest Endosc* 1998;48:465-9.
26. Wong WM, Wong BC, Hui CK, et al. Pyogenic liver abscess: retrospective analysis of 80 cases over a 10-year period. *J Gastroenterol Hepatol* 2002;17:1001-7.
27. Njoku VC, Howard TJ, Shen C, et al. Pyogenic Liver Abscess Following Pancreaticoduodenectomy: Risk Factors, Treatment, and Long-Term Outcome. *Journal of Gastrointestinal Surgery* 2014;18:922-928.

- 1
2
3 28. Rothlin MA, Lopfe M, Schlumpf R, et al. Long-term results of
4 hepaticojejunostomy for benign lesions of the bile ducts. *Am J Surg* 1998;175:22-6.
5
6 29. Chan KS, Chen CM, Cheng KC, et al. Pyogenic liver abscess: a retrospective
7 analysis of 107 patients during a 3-year period. *Jpn J Infect Dis* 2005;58:366-8.
8
9 30. Kang SC, Hwang SJ. Impact of advanced age on inpatients with pyogenic liver
10 abscess in Taiwan: a nationwide claim-based analysis. *J Chin Med Assoc*
11 2011;74:539-43.
12
13 31. Tian LT, Yao K, Zhang XY, et al. Liver abscesses in adult patients with and
14 without diabetes mellitus: an analysis of the clinical characteristics, features of the
15 causative pathogens, outcomes and predictors of fatality: a report based on a large
16 population, retrospective study in China. *Clin Microbiol Infect* 2012;18:E314-30.
17
18 32. Cheng HC, Chang WL, Chen WY, et al. Long-term outcome of pyogenic liver
19 abscess: factors related with abscess recurrence. *J Clin Gastroenterol* 2008;42:1110-5.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **Figure Legends**

48
49 Figure 1. Kaplan-Meier method determined the cumulative incidence of
50
51 pyogenic liver abscess compared between endoscopic sphincterotomy cohorts
52
53 and comparisons without endoscopic sphincterotomy.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Acknowledgements:

This study is supported in part by Taiwan Ministry of Health and Welfare

Clinical Trial

Center (MOHW106-TDU-B-212-113004), China Medical University

Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project

(BM10601010036), Taiwan Clinical Trial Consortium for Stroke(MOST

Age, mean(SD)†	68.5	14.6	66.9	15.0	0.11
Gender					
Women	3734	45.7	3832	46.9	0.02
Men	4440	54.3	4342	53.1	0.02
Comorbidity					
Congestive heart failure	564	6.90	491	6.01	0.04
Biliary stone	5695	69.7	5319	65.1	0.10
Cancer	687	8.40	580	7.10	0.06
Hypertension	3556	43.5	3186	39.0	0.09
Chronic obstructive lung disease	855	10.5	714	8.74	0.06
Hyperlipidemia	1052	12.9	792	9.69	0.10
Alcoholic liver damage	296	3.62	191	2.34	0.08
Cirrhosis	561	6.86	455	5.57	0.05
Cholangitis	793	9.70	1264	15.5	0.18
Cholecystitis	663	8.11	602	7.36	0.03
Pancreatic diseases	1544	18.9	1407	17.2	0.04
Chronic kidney disease	795	9.73	657	8.04	0.06
Appendicitis	167	2.04	152	1.86	0.01

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Inflammatory bowel					
disease	34	0.42	20	0.24	0.03
Diverticulosis	215	2.63	206	2.52	0.01

For peer review only

1 Table 2. Incidence and adjusted hazard ratio of Pyogenic liver abscess stratified by sex, age and
 2 comorbidity compared patients with and without endoscopic sphincterotomy

		Endoscopic sphincterotomy						Crude HR [†] (95 % CI)	Adjusted HR ^{&} (95 % CI)
		No			Yes				
		Event	PY	Rate [#]	Event	PY	Rate [#]		
All		33	35113	0.94	149	35454	4.20	4.50(3.08, 6.56)***	4.50(3.08, 6.58)***
Gender									
Women		12	16394	0.73	67	16970	3.95	5.42(2.93, 10.0)***	5.41(2.92, 10.0)***
Men		21	18719	1.12	82	18483	4.44	3.97(2.46, 6.42)***	4.02(2.48, 6.53)***
Age									
≤49		4	4928	0.81	23	5558	4.14	5.16(1.79, 14.9)**	7.30(2.42, 22.0)***
50-64		10	7762	1.29	38	8620	4.41	3.47(1.73, 6.96)***	3.30(1.63, 6.69)***
65+		19	22423	0.85	88	21276	4.14	4.90(2.99, 8.05)***	4.80(2.91, 7.90)***
Comorbidity									
No		2	4721	0.42	14	1715	8.16	20.4(4.60, 90.2)***	19.9(4.46, 88.6)***
Yes		31	30392	1.02	135	33738	4.00	3.95(2.67, 5.83)***	3.90(2.64, 5.78)***

3 Rate[#], incidence rate, per 1000 person-years

4 Crude HR[†], relative hazard ratio

5 Adjusted HR[&], adjusted hazard ratio, adjusted for age, sex, and comorbidity of congestive heart
 6 failure, biliary stone, cancer, hypertension, chronic obstructive lung disease, hyperlipidemia,

[Insert Running title of <72 characters]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 alcoholic liver damage, cirrhosis, cholangitis, cholecystitis, pancreatic diseases, chronic kidney
2 disease, appendicitis, inflammatory bowel disease, and diverticulosis.

3 *p<0.05, **p<0.01,***p<0.001

For peer review only

[Insert Running title of <72 characters]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3 Trends of Pyogenic liver abscess risks by stratified follow-up years

Endoscopic sphincterotomy									
		No			Yes				
Follow-up time, years	Event	PY	Rate [#]	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	
	1-2	11	15458	0.71	52	15319	3.39	4.81(2.51, 9.23)***	4.35(2.26, 8.39)***
2-3	15	9931	1.51	52	9785	5.31	3.54(1.99, 6.28)***	3.64(2.04, 6.50)***	
4-5	5	5512	0.91	22	5692	3.87	4.27(1.62, 11.3)**	4.59(1.72, 12.2)**	
>5	2	4213	0.47	23	4658	4.94	10.4(2.45, 44.0)**	12.1(2.80, 52.2)***	

1 Rate[#], incidence rate, per 1000 person-years

2 Crude HR[†], relative hazard ratio

3 Adjusted HR[‡], adjusted hazard ratio, adjusted for age, sex, and comorbidity of congestive heart
4 failure, biliary stone, cancer, hypertension, chronic obstructive lung disease, hyperlipidemia,
5 alcoholic liver damage, cirrhosis, cholangitis, cholecystitis, pancreatic diseases, chronic kidney
6 disease, appendicitis, inflammatory bowel disease, and diverticulosis.

7 *p<0.05, **p<0.01,***p<0.001

8
9
10
11
12
13
14
[Insert Running title of <72 characters]

1 Table 4. Cox Proportional Hazard Regression Analysis for the risk of pyogenic liver abscess by
 2 endoscopic sphincterotomy and Cholangitis


Variables		Event	Person-years	Rate [#]	Adjusted HR [†] (95% CI)	p-value [#]
Endoscopic sphincterotomy	Cholangitis					0.03
No	No	25	32177	0.78	1(Reference)	
No	Yes	8	2936	2.72	3.77(1.69, 8.41)**	
Yes	No	122	30378	4.02	5.48(3.56, 8.44)***	
Yes	Yes	27	5076	5.32	6.64(3.82, 11.5)***	

3 Rate[#], per 1,000 person-year;

4 † Model was adjusted for age, sex and other comorbidities. *p<0.05, **p<0.01, ***p<0.001

5 #p-value for interaction

[Insert Running title of <72 characters]



138x92mm (300 x 300 DPI)

view only

BMJ Open

The risk of pyogenic liver abscess and endoscopic sphincterotomy: A population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018818.R2
Article Type:	Research
Date Submitted by the Author:	08-Feb-2018
Complete List of Authors:	Peng, Yen-Chun ; Taichung Veterans General Hospital, Internal medicine; National Yang-Ming University, internal medicine Lin, Cheng-Li; China Medical University Hospital, Management Office for Health Data; China Medical University, College of Medicine Sung, Fung-Chang; China Medical University, School of Medicine; China Medical University, Institution of Clinical Medical Science
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Epidemiology
Keywords:	pyogenic liver abscess, endoscopic sphincterotomy, population based study

SCHOLARONE™
Manuscripts

The risk of pyogenic liver abscess and endoscopic sphincterotomy: A population-based cohort study

Yen-Chun Peng^{1,2}, Cheng-Li Lin^{3,4}, Fung-Chang Sung,^{3,5}

¹ Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

² National Yang-Ming University, Taipei, Taiwan

³ Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

⁴ College of Medicine, China Medical University, Taichung, Taiwan

⁵ Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

Address correspondence and requests for reprints to: Fung-Chang Sung, PhD.

Professor, Graduate Institute of Clinical Medical Science and School of Medicine,

College of Medicine, China Medical University, No. 2, Yuh-Der Road, Taichung 404,

Taiwan. Tel.: +886 4 22052121; Fax: +886 4 22336174. E-mail:sungfc2016@gmail.com

Abstract.

1 **Objectives:** To evaluate the risk pyogenic liver abscess (PLA) in patients receiving
2 endoscopic sphincterotomy (ES).
3

4 **Setting:** A population-based cohort study using data from Taiwans' National Health
5 Insurance Research Database was conducted. Patients aged 20 or older who had undergone
6 an ES were considered as the ES cohort. The dates for the first hospitalization of the ES
7 patients were defined as the index dates.
8

9 **Participants:** patients in the ES and non-ES cohorts were selected by 1:1 matching ratio
10 based on a propensity score. A total of 8174 sex-, age-, and index year-matched (1:1) pairs of
11 patients receiving ES and 8174 patients without ES served as controls. Cox proportional
12 hazards regression was employed to calculate the hazard ratios (HRs) and 95% confidence
13 intervals (CIs) for the association between PLA and ES.
14

15 **Results:** The overall incidence of PLA was significantly higher in the ES cohort than in the
16 non-ES cohort (4.20 vs 0.94, respectively, per 1000 person-year) with the adjusted HR (aHR)
17 = 4.50 (95% CI = 3.38-6.58) A stratified analysis during the follow-up years revealed that
18 when the ES cohort was compared with the non-ES cohort, they displayed a higher risk of
19 PLA during the first follow-up year (aHR = 4.35, 95% CI = 2.26-8.39) which continued
20 significantly over the next 4–5 years of follow-up.
21

22 **Conclusions:** Patients receiving ES are associated with having a higher risk of PLA.
23
24

25 **Article summary**

- 26
- 27 ➤ Endoscopic sphincterotomy is a procedure which eliminates the anatomic barrier of the
28 biliary tract and intestine, and is considered to be a well-established, standard procedure
29 for treating choledocholithiasis. There is no study have direct link the risk of pyogenic liver
30 abscess in patients receiving an Endoscopic sphincterotomy.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2 1 ➤ Patients receiving endoscopic sphincterotomy are associated with having a higher risk of
3
4 2 pyogenic liver abscess. The availability of these two large cohorts and follow-up
5
6 3 conducted in pyogenic liver abscess risk after patients receiving endoscopic
7
8 4 sphincterotomy.
9
10
11 5 ➤ We used the code for only endoscopic sphincterotomy, and the details of underlying
12
13 6 diseases, which included mostly biliary, and pancreatic diseases are not clearly defined
14
15 7 in the database.
16
17
18 8
19
20 9
21
22
23 10

25 Introduction

26
27 12 Endoscopic sphincterotomy (ES) is the most commonly used therapy for treatment of
28
29 13 common bile duct stones, and is today considered to be a well-established standard of
30
31 14 treatment for pancreato-biliary diseases. (1-3) Standard ES involves the application of
32
33 15 electrocautery to create an incision through the musculature of the biliary portion of the
34
35 16 sphincter of Oddi and its use is considered as a safe, therapeutic procedure. (4, 5)
36
37
38

39 17 Depending on the time frame after an ES, the complications resulting from an ES are
40
41 18 both short-term and long term. The percentage of short term complications is estimated to be
42
43 19 approximately 10 percent, where procedural related bleeding, perforation, pancreatitis, and
44
45 20 cardiopulmonary distress are considered as the short-term complications.(5) Long-term
46
47 21 complications following an ES include stone recurrence, papillary stenosis, and cholangitis,
48
49 22 any of which may which occur in approximately 6 to 24 percent of patients. (6-10)
50
51

52 23 Pyogenic liver abscesses (PLA) are the most common type of human visceral abscess.
53
54 24 The mechanism may be due to either the leakage of bowel contents or microbes which
55
56 25 subsequently spread to the liver via the portal circulation, or in the setting of a biliary infection.
57
58
59

1 Risk factors for PLA include diabetes mellitus, underlying hepatobiliary or pancreatic disease,
2 end-stage renal disease and the possible need for a liver transplant. (11-13) Additionally,
3 geographic and host associations should also be considered, such as *Klebsiella*
4 *pneumoniae* which has been experienced in East Asia.(14)

5 Regarding the long-term follow-up after ES, most previous studies displayed recurrent
6 biliary stones, cholangitis, stenosis and malignancy. (7-10, 15-17)

7 ES creates a communication of bowel contents to both the biliary system, and liver. Thus,
8 it is reasonable to consider that PLA is associated with ES. Up until now, there has been a
9 lack of data associating the risk of PLA with ES.

10
11 To illuminate the risk of PLA and ES, we conducted a population-based, cohort study to
12 analyze the risk of PLA among patients receiving an ES.

13 14 **Materials and Methods**

15 **Data Source**

16 This was a longitudinal, cohort study using the National Health Institute Research Database
17 (NHIRD) of the National Health Insurance (NHI) program in Taiwan. The NHI program began
18 in 1995, and 99% of the 23.74 million Taiwan residents became covered (18). The details of
19 the NHI program and the NHIRD have been well documented in previous studies (16, 19).
20 Diseases were coded in the NHIRD according to the 2001 International Classification of
21 Diseases, Ninth revision, Clinical Modification (ICD-9-CM). This study was approved by the
22 Institutional Review Board (IRB) of China Medical University and Hospital in Taiwan
23 (CMUH104-REC2-115).

24 **Sampled Participants**

1 Patients aged 20 or older years who had undergone an ES (ICD-9-OP 51.84) were
2 considered as the ES cohort. The dates for the first hospitalization of the ES patients were
3 defined as the index dates. We excluded patients younger than 20 years, along with those
4 having a history of PLA (ICD-9-CM code 572.0) before the index date, any PLA diagnosed
5 within 1 year after the index date, a history of amoebic liver abscess (ICD-9-CM code 006.3),
6 and/or those lacking information on their age and sex. The non-ES cohort was identified
7 during the same period occurring from the years 2000-2010, with exclusion criteria similar to
8 the ES cohort. Patients in the ES and non-ES cohorts were selected by a 1:1 matching ratio
9 based on a propensity score (20). The propensity score was calculated using a logistic
10 regression to estimate the probability of the disease assignment, based on the baseline
11 variables, including year of ES diagnosis, age, gender, and comorbidities of congestive heart
12 failure (ICD-9-CM code 428), biliary stone (ICD-9-CM code 574), cancer (ICD-9-CM codes
13 140-208), hypertension (ICD-9-CM codes 401-405), chronic obstructive pulmonary disease
14 (ICD-9-CM codes 491, 492, 496), hyperlipidemia (ICD-9-CM code 272), alcoholic liver
15 damage (ICD-9-CM code 571.0, 571.1, and 571.3), cirrhosis (ICD-9-CM codes 571.2, 571.5,
16 and 571.6), cholangitis (ICD-9-CM code 576.1), cholecystitis (ICD-9-CM code 575),
17 pancreatic diseases (ICD-9-CM code 577), chronic kidney disease (ICD-9-CM codes
18 580-589), appendicitis (ICD-9-CM codes 540-543), inflammatory bowel disease (ICD-9-CM
19 codes 555, 556), and diverticulosis (ICD-9-CM codes 562).

20 **Follow-up and Outcome**

21 All of the patients were monitored up until either a diagnosis of PLA was made, they were
22 censored for withdrawal from the NHI program, their death, or December 31, 2011, whichever
23 occurred first.

24 **Statistical analysis**

1 Distributions in demographic variables, including age, gender, and comorbidities were
2 compared between the ES and non-ES cohorts. The baseline characteristics of the ES and
3 non-ES cohorts were compared using standardized mean differences (21). A value of
4 standardized mean differences equaled .1 or less, which indicates there was a negligible
5 difference in means between ES and non-ES cohorts. Incidence density rates of PLA by
6 gender, age, and comorbidity were calculated in both cohorts. We assessed the cumulative
7 incidence of PLA by using the Kaplan-Meier method in both the ES and non- ES cohorts, with
8 significance based on the log-rank test. Univariable and multivariable Cox proportional hazard
9 regressions were performed to measure the overall, gender-, age-, comorbidity-, follow-up
10 years- risk of developing PLA. Hazard ratios (HRs) and 95% confidence intervals (CIs) were
11 also estimated in the Cox model. The multivariate models were simultaneously adjusted for
12 age, sex, and the comorbidities of congestive heart failure, biliary stone, cancer, hypertension,
13 chronic obstructive pulmonary disease, hyperlipidemia, alcoholic liver damage, cirrhosis,
14 cholangitis, cholecystitis, pancreatic diseases, chronic kidney disease, appendicitis,
15 inflammatory bowel disease, and diverticulosis. The entire matching procedure and all
16 statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). A
17 two-tailed $P < .05$ was considered significant.

18 **Results**

19 **Characteristics of patients**

20 Our study cohort consisted of 8,174 patients with ES and 8,174 patients without ES. The
21 mean age (\pm SD) of the ES and non-ES cohorts was 66.9 ± 15.0 and 68.5 ± 14.6 years,
22 respectively (Table 1). Most patients were men (53.1%). The major comorbidities were biliary
23 stone (65.1% vs. 69.7%), and hypertension (39.0% vs. 43.5%) in these study cohorts,
24 followed by pancreatic diseases (17.2% vs. 18.9%), cholangitis (15.5% vs. 9.70%) and
25 hyperlipidemia (9.69% vs. 12.9%). The average follow-up duration was 4.33 ± 2.71 years for

1 the ES cohort and 4.30 ± 2.60 years for the non-ES cohort, respectively. Figure 1 shows that
2 the cumulative incidence of PLA was higher in the ES cohort than that in the non-ES cohort by
3 3.33% at the end of the follow-up period (log-rank test $P < 0.001$).

4 **Incidence and adjusted hazard ratio of PLA after ES**

5 The overall incidence of PLA was significantly higher in the ES cohort than in the non-ES
6 cohort (4.20 vs 0.94, respectively, per 1000 person-year) with the adjusted HR (aHR) = 4.50
7 (95% CI = 3.38-6.58) (Table 2). The ES cohort to the non-ES cohort aHR of PLA was
8 significant for each status (including gender, age group, and those with or without
9 comorbidity).

10 **Trend of PLA risk by stratified follow-up years**

11 A stratified analysis of the follow-up years revealed that the ES cohort when compared with
12 the non-ES cohort, had higher risk of PLA during the first follow-up year (aHR = 4.35, 95% CI
13 = 2.26-8.39) and remained significantly so during 4–5 years of follow-up (aHR = 4.59, 95% CI
14 = 1.72-12.2). The risk of PLA remained even beyond 5 years of follow-up (aHR = 12.1, 95% CI
15 = 2.80-52.2) (Table 3).

16 **Risk of Pyogenic liver abscess by Endoscopic sphincterotomy and Cholangitis**

17 Table 4 outlines the interaction effects of ES and cholangitis towards the risk of PLA. Relative
18 to the non-ES cohort without cholangitis, the ES patients with cholangitis were at a much
19 higher risk of PLA (aHR=6.64, 95% CI=3.82-11.5), when compared to patients with only
20 cholangitis (aHR=3.77, 95% CI=1.69-8.41) or with only ES (aHR=5.48, 95% CI=3.56-8.44)
21 (Table 4, the P-value of interaction=0.03).

22 **Discussion**

23 The association between PLA and ES is demonstrated by our results, which show that
24 patients receiving ES have higher incidence rates of PLA than those in the control group (4.02
25 vs. 0.94 cases per 1000 person-years, $p < 0.001$). The adjusted HR for PLA was found to be

1 4.50 (95% CI 3.08–6.58) for patients receiving EST, after adjusting for age, sex, and any
2 possible comorbidities. The risk becomes even more significant when the follow-up years
3 exceed 5 (adjust HR12.1, 95% CI 2.80- 52.2). Thus, PLA would be considered as one of the
4 events which is associated with EST during long-term follow-up. ES experience is also
5 considered to be one of the risks of PLA.

6 There is no clearly set time for the duration of follow-up when discussing the long-term
7 complications of ES. A hospital-based study regarding endoscopic retreatment for biliary
8 stones after ES is defined to be 5 years, and then a follow-up choledochal conditions due to
9 increased risk of complications is suggested. (22) According to our results, PLA risk was
10 determined to occur within 1 year after ES, and could be found to be increasing even more
11 than that during the 5 year span. Thus, PLA risk would be need to be carefully monitored
12 throughout follow-up. Risk of PLA was found to be more significant in non-comorbridity and
13 young aged patients. We could explain that elderly patients and those experiencing
14 co-morbidity carry a higher risk of PLA.

15 After decades of development, ES is still considered to be the requisite standard of care,
16 and therefore has become the most commonly used procedure for the endoscopic treatment
17 of biliay diseases, including choledocholithiasis. ES is applied to cut the biliary sphincter in
18 order to eliminate the principal anatomic barrier impeding stone passage, and facilitate biliary
19 manipulation. Upon reviewing available literature, long-term choledochal complications after
20 ES include recurrent cholangitis, choledocholithiasis, biliary stenosis and cholecystitis. (6-10,
21 17) After ES, the anatomic barrier of the hepato-biliary system and intestine is removed,
22 resulting in the communication causing an ascending migration of the bowel contents. The
23 ascending movement would not be limited to strictly the biliary system only. Intrahepatic
24 biliary system and even in hepatic cananliculi would be involved. Patients experiencing ES
25 would remain under the risk of PLA.

1
2 1 There seemed to be no large survey for PLA after ES except for case reports.(23, 24)
3
4 2 Taneka et al report about 5 PLA in 419 ES patients in a long-term follow up for ES study. (25)
5
6 3 Interestingly, a smaller study about PLA demonstrated that patients with ES is good
7
8 prognostic factor associated resolution within 6 weeks.(26) Based on the communicating with
9
10 4 intestine, risk of PLA were also found in patients receiving pancreatitcoduodenostomy, and
11
12 5 hepatojejunostomy. (27, 28)
13
14 6

15
16 7 PLA has become a worldwide health problem that is not limited to only Taiwan. When
17
18 8 focusing on the risks of PLA, diabetes, end-stage renal disease, hepatobiliary diseases,
19
20 9 pancreatic diseases, and the need for a liver transplant are all considered risk factors. (11-13,
21
22 10 29-31) Biliary disease is also considered as a risk of PLA, but there is lack of mention to ES.
23
24 11 (32) Based on our results, patients receiving ES would also be considered to be a risk of PLA.
25
26

27 12 In the study, we first defined the association between ES and PLA, and recognized ES
28
29 13 as a definite risk factor for PLA. There are however several limitations for the present study.
30
31 14 First, we used the code for only ES, and any underlying diseases, which included mostly
32
33 15 biliary, and pancreatic diseases. However, we did adjust both biliary and pancreatic disease,
34
35 16 as shown in table 1. Second, the follow-up duration is around 4.3 years, with the longest set at
36
37 17 about 7 years, due to the limitations of the database. We would expect to see a more
38
39 18 significant PLA risk appearing under a longer follow-up period.
40
41
42

43 19 Our results demonstrate a significant risk of PLA during follow-up periods for patients
44
45 20 receiving ES. Further investigations including bacterial culture, details of biliary systems and
46
47 21 the analysis of clinical data, would be valuable studies that could be performed under a
48
49 22 hospital-based inquiry.
50
51
52
53
54
55
56
57
58
59
60

Contributor ship statement

Author contributions: Conception and design: Yen-Chun Peng, Cheng-Li Lin, Fung-Chang Sung; Administrative support: Yen-Chung Peng; Collection and assembly of data: Yen-Chun Peng, Cheng-Li Lin, Fung-Chang Sung; Data analysis and interpretation: Yen-Chung Peng, Cheng-Li Lin, Fung-Chang Sung; Manuscript writing and revision: all authors; Final approval of manuscript: all authors.

competing interests

The authors declare no competing interests

Funding

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10601010036), Taiwan Clinical Trial Consortium for Stroke(MOST 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.

Data sharing statement

The Ministry of Health and Welfare must approved our application to access this data.

Any researcher interested in accessing this dataset can submit an application form to the Ministry of Health and Welfare requesting access. Please contact the staff of

1
2
3
4 MOHW (Email: stcarolwu@mohw.gov.tw) for further assistance. Taiwan Ministry of
5
6 Health and Welfare Address: No.488, Sec. 6, Zhongxiao E. Rd., Nangang Dist.,
7
8
9 Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848. All relevant data are
10
11
12 within the paper.
13
14
15
16
17

18 **References**

- 20 1. Dumonceau JM, Delhaye M, Tringali A, et al. Endoscopic treatment of chronic
21 pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Clinical
22 Guideline. *Endoscopy* 2012;44:784-800.
- 23 2. Maple JT, Ben-Menachem T, Anderson MA, et al. The role of endoscopy in the
24 evaluation of suspected choledocholithiasis. *Gastrointest Endosc* 2010;71:1-9.
- 25 3. Williams EJ, Green J, Beckingham I, et al. Guidelines on the management of
26 common bile duct stones (CBDS). *Gut* 2008;57:1004-21.
- 27 4. Binmoeller KF, Schafer TW. Endoscopic management of bile duct stones. *J Clin*
28 *Gastroenterol* 2001;32:106-18.
- 29 5. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary
30 sphincterotomy. *N Engl J Med* 1996;335:909-18.
- 31 6. Hawes RH, Cotton PB, Vallon AG. Follow-up 6 to 11 years after duodenoscopic
32 sphincterotomy for stones in patients with prior cholecystectomy. *Gastroenterology*
33 1990;98:1008-12.
- 34 7. Wojtun S, Gil J, Gietka W, et al. Endoscopic sphincterotomy for
35 choledocholithiasis: a prospective single-center study on the short-term and long-term
36 treatment results in 483 patients. *Endoscopy* 1997;29:258-65.
- 37 8. Yasuda I, Fujita N, Maguchi H, et al. Long-term outcomes after endoscopic
38 sphincterotomy versus endoscopic papillary balloon dilation for bile duct stones.
39 *Gastrointest Endosc* 2010;72:1185-91.
- 40 9. Sugiyama M, Suzuki Y, Abe N, et al. Endoscopic retreatment of recurrent
41 choledocholithiasis after sphincterotomy. *Gut* 2004;53:1856-9.
- 42 10. Sugiyama M, Atomi Y. Follow-up of more than 10 years after endoscopic
43 sphincterotomy for choledocholithiasis in young patients. *Br J Surg* 1998;85:917-21.
- 44 11. Mohsen AH, Green ST, Read RC, et al. Liver abscess in adults: ten years
45 experience in a UK centre. *Qjm* 2002;95:797-802.

12. Thomsen RW, Jepsen P, Sorensen HT. Diabetes mellitus and pyogenic liver abscess: risk and prognosis. *Clin Infect Dis* 2007;44:1194-201.
13. Tsai LW, Chao PW, Ou SM, et al. Pyogenic liver abscess in end-stage renal disease patients: a nationwide longitudinal study. *Hemodial Int* 2015;19:72-9.
14. Tsai F-C, Huang Y-T, Chang L-Y, et al. Pyogenic Liver Abscess as Endemic Disease, Taiwan. *Emerging Infectious Diseases* 2008;14:1592-1600.
15. Kalaitzis J, Vezakis A, Fragulidis G, et al. Effects of endoscopic sphincterotomy on biliary epithelium: a case-control study. *World J Gastroenterol* 2012;18:794-9.
16. Peng YC, Lin CL, Hsu WY, et al. Association of Endoscopic Sphincterotomy or Papillary Balloon Dilatation and Biliary Cancer: A Population-Based Cohort Study. *Medicine (Baltimore)* 2015;94:e926.
17. Sugiyama M, Atomi Y. Risk factors predictive of late complications after endoscopic sphincterotomy for bile duct stones: long-term (more than 10 years) follow-up study. *Am J Gastroenterol* 2002;97:2763-2767.
18. Database NHIR. Taiwan, <http://nhird.nhri.org.tw/en/index.html>. 2015.
19. Wang CC, Chang CT, Lin CL, et al. Spinal cord injury is associated with an increased risk of atrial fibrillation: A population-based cohort study. *Heart Rhythm* 2016;13:416-23.
20. Parsons LS, Ovation Research Group. SUGI 29. Seattle, Washington; 2004. Performing a 1:N Case-Control Match on Propensity Score; pp. 165–29.
21. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009;28:3083-107.
22. Keizman D, Shalom MI, Konikoff FM. An angulated common bile duct predisposes to recurrent symptomatic bile duct stones after endoscopic stone extraction. *Surg Endosc* 2006;20:1594-9.
23. Correa Bonito A, Mora-Guzman I, Garcia-Sanz I, et al. Liver abscess after endoscopic retrograde cholangiopancreatography with presence of *Actinomyces naeslundii*. *Cir Esp* 2017;95:51-52.
24. Gavini S, Kadiyala S, Venkatarami Reddy V, et al. Large liver abscess after ERCP and laparoscopic cholecystectomy. *HPB*;18:e315-e316.
25. Tanaka M, Takahata S, Konomi H, et al. Long-term consequence of endoscopic sphincterotomy for bile duct stones. *Gastrointest Endosc* 1998;48:465-9.
26. Wong WM, Wong BC, Hui CK, et al. Pyogenic liver abscess: retrospective analysis of 80 cases over a 10-year period. *J Gastroenterol Hepatol* 2002;17:1001-7.
27. Njoku VC, Howard TJ, Shen C, et al. Pyogenic Liver Abscess Following Pancreaticoduodenectomy: Risk Factors, Treatment, and Long-Term Outcome. *Journal of Gastrointestinal Surgery* 2014;18:922-928.

- 1
2
3 28. Rothlin MA, Lopfe M, Schlumpf R, et al. Long-term results of
4 hepaticojejunostomy for benign lesions of the bile ducts. *Am J Surg* 1998;175:22-6.
5
6 29. Chan KS, Chen CM, Cheng KC, et al. Pyogenic liver abscess: a retrospective
7 analysis of 107 patients during a 3-year period. *Jpn J Infect Dis* 2005;58:366-8.
8
9 30. Kang SC, Hwang SJ. Impact of advanced age on inpatients with pyogenic liver
10 abscess in Taiwan: a nationwide claim-based analysis. *J Chin Med Assoc*
11 2011;74:539-43.
12
13 31. Tian LT, Yao K, Zhang XY, et al. Liver abscesses in adult patients with and
14 without diabetes mellitus: an analysis of the clinical characteristics, features of the
15 causative pathogens, outcomes and predictors of fatality: a report based on a large
16 population, retrospective study in China. *Clin Microbiol Infect* 2012;18:E314-30.
17
18 32. Cheng HC, Chang WL, Chen WY, et al. Long-term outcome of pyogenic liver
19 abscess: factors related with abscess recurrence. *J Clin Gastroenterol* 2008;42:1110-5.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Figure Legends**

56
57
58
59
60

1
2
3 Figure 1. Kaplan-Meir method determined the cumulative incidence of
4 pyogenic liver abscess compared between endoscopic sphincterotomy cohorts
5 and comparisons without endoscopic sphincterotomy.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **Acknowledgements:**
53
54
55
56
57
58
59
60

1
2
3 This study is supported in part by Taiwan Ministry of Health and Welfare
4
5 Clinical Trial
6
7 Center (MOHW106-TDU-B-212-113004), China Medical University
8
9 Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project
10
11 (BM10601010036), Taiwan Clinical Trial Consortium for Stroke(MOST
12
13 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan
14
15 Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo
16
17 AoshimaMemorial Funds, Japan.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Table 1. Comparisons in demographic characteristics and comorbidities between
50
51 patients with and without endoscopic sphincterotomy
52

Endoscopic sphincterotomy	Standard
---------------------------	----------

	No		Yes		difference
	(n=8174)		(n=8174)		
	n	%	n	%	
Age, mean(SD)†	68.5	14.6	66.9	15.0	0.11
Gender					
Women	3734	45.7	3832	46.9	0.02
Men	4440	54.3	4342	53.1	0.02
Comorbidity					
Congestive heart failure	564	6.90	491	6.01	0.04
Biliary stone	5695	69.7	5319	65.1	0.10
Cancer	687	8.40	580	7.10	0.06
Hypertension	3556	43.5	3186	39.0	0.09
Chronic obstructive lung disease	855	10.5	714	8.74	0.06
Hyperlipidemia	1052	12.9	792	9.69	0.10
Alcoholic liver damage	296	3.62	191	2.34	0.08
Cirrhosis	561	6.86	455	5.57	0.05
Cholangitis	793	9.70	1264	15.5	0.18
Cholecystitis	663	8.11	602	7.36	0.03

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pancreatic diseases	1544	18.9	1407	17.2	0.04
Chronic kidney disease	795	9.73	657	8.04	0.06
Appendicitis	167	2.04	152	1.86	0.01
Inflammatory bowel disease	34	0.42	20	0.24	0.03
Diverticulosis	215	2.63	206	2.52	0.01

For peer review only

1 Table 2. Incidence and adjusted hazard ratio of Pyogenic liver abscess stratified by sex, age and
 2 comorbidity compared patients with and without endoscopic sphincterotomy

		Endoscopic sphincterotomy						Crude HR [†] (95 % CI)	Adjusted HR ^{&} (95 % CI)
		No			Yes				
		Event	PY	Rate [#]	Event	PY	Rate [#]		
All		33	35113	0.94	149	35454	4.20	4.50(3.08, 6.56)***	4.50(3.08, 6.58)***
Gender									
	Women	12	16394	0.73	67	16970	3.95	5.42(2.93, 10.0)***	5.41(2.92, 10.0)***
	Men	21	18719	1.12	82	18483	4.44	3.97(2.46, 6.42)***	4.02(2.48, 6.53)***
Age									
	≤49	4	4928	0.81	23	5558	4.14	5.16(1.79, 14.9)**	7.30(2.42, 22.0)***
	50-64	10	7762	1.29	38	8620	4.41	3.47(1.73, 6.96)***	3.30(1.63, 6.69)***
	65+	19	22423	0.85	88	21276	4.14	4.90(2.99, 8.05)***	4.80(2.91, 7.90)***
Comorbidity									
	No	2	4721	0.42	14	1715	8.16	20.4(4.60, 90.2)***	19.9(4.46, 88.6)***
	Yes	31	30392	1.02	135	33738	4.00	3.95(2.67, 5.83)***	3.90(2.64, 5.78)***

3 Rate[#], incidence rate, per 1000 person-years

4 Crude HR[†], relative hazard ratio

5 Adjusted HR[&], adjusted hazard ratio, adjusted for age, sex, and comorbidity of congestive heart
 6 failure, biliary stone, cancer, hypertension, chronic obstructive lung disease, hyperlipidemia,

[Insert Running title of <72 characters]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 alcoholic liver damage, cirrhosis, cholangitis, cholecystitis, pancreatic diseases, chronic kidney
2 disease, appendicitis, inflammatory bowel disease, and diverticulosis.

3 *p<0.05, **p<0.01,***p<0.001

For peer review only

[Insert Running title of <72 characters]

1
23 Table 3 Trends of Pyogenic liver abscess risks by stratified follow-up years
4

Endoscopic sphincterotomy									
		No			Yes				
Follow-up time, years	Event	PY	Rate [#]	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	
	1-2	11	15458	0.71	52	15319	3.39	4.81(2.51, 9.23)***	4.35(2.26, 8.39)***
2-3	15	9931	1.51	52	9785	5.31	3.54(1.99, 6.28)***	3.64(2.04, 6.50)***	
4-5	5	5512	0.91	22	5692	3.87	4.27(1.62, 11.3)**	4.59(1.72, 12.2)**	
>5	2	4213	0.47	23	4658	4.94	10.4(2.45, 44.0)**	12.1(2.80, 52.2)***	

23

24 1 Rate[#], incidence rate, per 1000 person-years

25

26 2 Crude HR[†], relative hazard ratio

27

28 3 Adjusted HR[‡], adjusted hazard ratio, adjusted for age, sex, and comorbidity of congestive heart

29

30 4 failure, biliary stone, cancer, hypertension, chronic obstructive lung disease, hyperlipidemia,

31

32 5 alcoholic liver damage, cirrhosis, cholangitis, cholecystitis, pancreatic diseases, chronic kidney

33

34 6 disease, appendicitis, inflammatory bowel disease, and diverticulosis.

35

36 7 *p<0.05, **p<0.01,***p<0.001

37

38 8

39

40 9

41

42 10

43

44 11

45

46 12

47

48 13

49

50 14

51

52 [Insert Running title of <72 characters]

53

54

55

56

57

58

59

60

1 Table 4. Cox Proportional Hazard Regression Analysis for the risk of pyogenic liver abscess by
 2 endoscopic sphincterotomy and Cholangitis

Variables		Event	Person-years	Rate [#]	Adjusted HR [†] (95% CI)	p-value [#]
Endoscopic sphincterotomy	Cholangitis					0.03
No	No	25	32177	0.78	1(Reference)	
No	Yes	8	2936	2.72	3.77(1.69, 8.41)**	
Yes	No	122	30378	4.02	5.48(3.56, 8.44)***	
Yes	Yes	27	5076	5.32	6.64(3.82, 11.5)***	


3 Rate[#], per 1,000 person-year;

4 † Model was adjusted for age, sex and other comorbidities. *p<0.05, **p<0.01, ***p<0.001

5 #p-value for interaction

[Insert Running title of <72 characters]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



138x92mm (300 x 300 DPI)

view only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4, 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4,5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4,5
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	6
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6,7,
		(b) Indicate number of participants with missing data for each variable of interest	-
		(c) Summarise follow-up time (eg, average and total amount)	6, 7
Outcome data	15*	Report numbers of outcome events or summary measures over time	7
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	7
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			
Key results	18	Summarise key results with reference to study objectives	7, 8
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	10

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.